Published in Cancer Metastasis Rev on December 01, 2011
Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun (2012) 1.04
Current evidence linking polyunsaturated Fatty acids with cancer risk and progression. Front Oncol (2013) 0.98
The Antitumor Effects of Triterpenoid Saponins from the Anemone flaccida and the Underlying Mechanism. Evid Based Complement Alternat Med (2013) 0.91
Inflammation and cancer: role of annexin A1 and FPR2/ALX in proliferation and metastasis in human laryngeal squamous cell carcinoma. PLoS One (2014) 0.91
Inhibitory effects of traditional herbal formula pyungwi-san on inflammatory response in vitro and in vivo. Evid Based Complement Alternat Med (2013) 0.89
Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Res Treat (2013) 0.88
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology (2013) 0.88
Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway. Oncotarget (2015) 0.87
Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Prostaglandins Other Lipid Mediat (2014) 0.86
Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. Int J Mol Sci (2015) 0.86
Taurocholate Induces Cyclooxygenase-2 Expression via the Sphingosine 1-phosphate Receptor 2 in a Human Cholangiocarcinoma Cell Line. J Biol Chem (2015) 0.85
Ratio of n-3/n-6 PUFAs and risk of breast cancer: a meta-analysis of 274135 adult females from 11 independent prospective studies. BMC Cancer (2014) 0.82
Cyclooxygenase-2 in tumor-associated macrophages promotes breast cancer cell survival by triggering a positive-feedback loop between macrophages and cancer cells. Oncotarget (2015) 0.81
Clinical evidence for the use of aspirin in the treatment of cancer. Ecancermedicalscience (2013) 0.81
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer. J Cancer Res Clin Oncol (2013) 0.80
miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). Oncotarget (2015) 0.80
"Dead Cells Talking": The Silent Form of Cell Death Is Not so Quiet. Biochem Res Int (2012) 0.79
Cellular uptake and antiproliferative effects of 11-oxo-eicosatetraenoic acid. J Lipid Res (2013) 0.78
Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer. Breast Cancer (Auckl) (2016) 0.78
Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer. Am J Cancer Res (2014) 0.78
Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state. Transl Res (2016) 0.77
COX-2 induces lytic reactivation of EBV through PGE2 by modulating the EP receptor signaling pathway. Virology (2015) 0.77
Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model. Cancer Biol Ther (2015) 0.77
Prostaglandin E2 stimulates normal bronchial epithelial cell growth through induction of c-Jun and PDK1, a kinase implicated in oncogenesis. Respir Res (2015) 0.76
Can Aspirin and Cancer Prevention be Ageless Companions? J Clin Diagn Res (2015) 0.76
Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2. Oncoimmunology (2015) 0.75
Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis. Am J Cancer Res (2015) 0.75
Role of Modulator of Inflammation Cyclooxygenase-2 in Gammaherpesvirus Mediated Tumorigenesis. Front Microbiol (2017) 0.75
Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. Int J Biol Sci (2016) 0.75
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer. Oncotarget (2016) 0.75
GPCR Signaling Mediates Tumor Metastasis via PI3Kβ. Cancer Res (2016) 0.75
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells. Redox Biol (2017) 0.75
PGE2-EP3 signaling exacerbates intracerebral hemorrhage outcomes in 24-mo-old mice. Am J Physiol Heart Circ Physiol (2016) 0.75
Prostaglandin dehydrogenase is a target for successful induction of cervical ripening. Proc Natl Acad Sci U S A (2017) 0.75
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Aspirin use and reduced risk of fatal colon cancer. N Engl J Med (1991) 7.85
Eicosanoids and cancer. Nat Rev Cancer (2010) 5.96
Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol (2008) 5.30
Prostaglandin E receptors. J Biol Chem (2007) 5.29
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis (2009) 5.01
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res (2007) 4.69
Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res (1995) 4.52
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Aspirin intake and survival after breast cancer. J Clin Oncol (2010) 4.50
Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol (2001) 4.40
Prostaglandins as modulators of immunity. Trends Immunol (2002) 4.15
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem (2001) 3.69
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov (2011) 3.31
Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) (2011) 2.97
A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst (2007) 2.95
EP2 and EP4 prostanoid receptor signaling. Life Sci (2003) 2.87
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res (1995) 2.74
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell (2003) 2.71
Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med (2009) 2.68
Prostaglandins and breast cancer. Lancet (1977) 2.54
Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res (2003) 2.49
Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst (2008) 2.44
Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med (2009) 2.41
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res (2005) 2.32
Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology (1996) 2.30
Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A (2003) 2.23
Breast cancer and NSAID use: a meta-analysis. Br J Cancer (2001) 2.21
Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology (1996) 2.11
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res (2007) 2.03
Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest (2001) 1.99
Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst (1980) 1.93
Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A (1996) 1.88
Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev (2007) 1.72
Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer (2006) 1.71
Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med (2003) 1.69
Inhibition of murine natural killer cell activity by prostaglandins. J Immunol (1980) 1.68
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer (2001) 1.61
Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control (2006) 1.52
Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res (2008) 1.52
Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res (2006) 1.46
COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol (2005) 1.45
Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol (2007) 1.44
G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol (2006) 1.44
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44
Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res (2002) 1.42
COX-2 involvement in breast cancer metastasis to bone. Oncogene (2007) 1.40
Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res (2006) 1.40
COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer (2006) 1.39
Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins. J Biol Chem (1993) 1.37
EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem (2007) 1.36
Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res (2003) 1.36
Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol (2006) 1.36
Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 receptors. Can J Physiol Pharmacol (2006) 1.35
The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res (2005) 1.33
Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci U S A (1996) 1.33
Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur J Biochem (1993) 1.33
Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst (1980) 1.32
Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Mol Cancer Res (2010) 1.32
Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer (2006) 1.32
Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci U S A (1998) 1.29
Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res (2006) 1.28
Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem (1999) 1.27
Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst (1993) 1.26
Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer (2001) 1.24
Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int J Biochem Cell Biol (2009) 1.23
Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer (2005) 1.21
Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry (1994) 1.20
Prostaglandin receptors: advances in the study of EP3 receptor signaling. J Biochem (2002) 1.16
Prostaglandin E2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through an EP1/EP3-dependent mechanism. J Immunol (2000) 1.15
Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer (2008) 1.14
Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE. J Immunol (1995) 1.14
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res (2007) 1.14
The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res (2007) 1.13
PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis. Mol Pharmacol (2007) 1.13
Retracted Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway. J Biol Chem (2006) 1.13
NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat (2007) 1.12
Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab (2003) 1.12
Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. J Invest Dermatol (2006) 1.12
Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem (2008) 1.12
Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in cDNA-transfected Chinese hamster ovary cells. Biochim Biophys Acta (1995) 1.09
Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol Pharmacol (1995) 1.09
Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res (2010) 1.08
EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol Pharmacol (2005) 1.08
Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother (2008) 1.08
Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer (2002) 1.07
mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie (2010) 1.07
Regulation of eNOS expression in brain endothelial cells by perinuclear EP(3) receptors. Circ Res (2002) 1.07
Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat (2008) 1.07
Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1. Cancer Res (2009) 1.06
Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res (2004) 1.05
The modulation of human natural killer cell activity by prostaglandins. J Clin Lab Immunol (1982) 1.05
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol (2013) 1.53
CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther (2009) 1.43
Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition. Am J Physiol Cell Physiol (2009) 1.27
Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat (2008) 1.07
Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother (2011) 1.00
An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. Cancer Res (2004) 0.94
Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer (2006) 0.90
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology (2013) 0.88
Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Res Treat (2013) 0.88
Antimetastatic activity isolated from Colocasia esculenta (taro). Anticancer Drugs (2012) 0.75
Diagnostic imaging in veterinary dental practice. Foreign body with secondary bacterial component. J Am Vet Med Assoc (2012) 0.75